Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

Table 4

Markov model input parameters for chronic pouchitis.

Health states	Transition probabilities (%)/cycle	Costs (CA$)/cycle	Utility scores/year
(M) Response to ADA 1		4,442 (±25%)	0.58 (±0.15)
(1) Response to ADA 1	See Table 5
(2) Lost response (unwell 1)	#
(3) ADA complication 1	4.20
(N) Unwell 1		917 (±25%)	0.32 (±0.31)
(1) Unwell 1	#
(2) Surgery 1	10.00
(3) Steroid complication 1	2.80
(O1) ADA complication 1 in the ADA not available arm		12,059 (±25%)	0.16 (±0.16)
(1) Response to ADA 1	60.00
(2) Unwell 1	19.00
(3) Surgery 1	19.00
(4) Death	#
(O2) ADA complication 1 in the ADA available arm		12,059 (±25%)	0.16 (±0.16)
(1) Response to ADA 1	51.00
(2) Unwell 1	23.50
(3) Surgery 1	23.50
(4) Death	#
(P) Surgery 1 (permanent ileostomy)		37,159 (±25%)	0.16 (±0.16)
(1) Response 1	#
(2) Surgery complication 1	12.80
(3) Death	2.50
(Q) Steroid complication 1		23,919 (±25%)	0.16 (±0.16)
(1) Surgery 1	98.00
(2) Death	#
(R) Response to surgery 1		0	0.44 (±0.11)
(1) Response to surgery 1	#
(2) Surgical complication 1	2.50
(S) Surgical complication 1		17,586 (±25%)	0.37 (±0.24)
(1) Response to surgery	#
(2) Death	0.50

#: complement probability.